Alkylating Agent–Induced NRF2 Blocks Endoplasmic Reticulum Stress–Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis
Open accessPublished version of a preprint
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Alkylating agents are a commonly used cytotoxic class of anticancer drugs. Understanding the mechanisms whereby cells respond to these drugs is key to identify means to improve therapy while reducing toxicity. By integrating genome-wide gene expression profiling, protein analysis, and functional cell validation, we herein demonstrated a direct relationship between NRF2 and Endoplasmic Reticulum (ER) stress pathways in response to alkylating agents, which is coordinated by the availability of glutathione (GSH) pools. GSH is essential for both drug detoxification and protein thiol homeostasis within the ER, thus inhibiting ER stress induction and promoting survival, an effect independent of its antioxidant role. NRF2 accumulation induced by alkylating agents resulted in increased GSH synthesis via GCLC/GCLM enzyme, and interfering with this NRF2 response by either NRF2 knockdown or GCLC/GCLM inhibition with buthionine sulfoximine caused accumulation of damaged proteins within the ER, leading to PERK-dependent apoptosis. Conversely, upregulation of NRF2, through KEAP1 depletion or NRF2-myc overexpression, or increasing GSH levels with N-acetylcysteine or glutathione-ethyl-ester, decreased ER stress and abrogated alkylating agents–induced cell death. Based on these results, we identified a subset of lung and head-and-neck carcinomas with mutations in either KEAP1 or NRF2/NFE2L2 genes that correlate with NRF2 target overexpression and poor survival. In KEAP1-mutant cancer cells, NRF2 knockdown and GSH depletion increased cell sensitivity via ER stress induction in a mechanism specific to alkylating drugs. Overall, we show that the NRF2-GSH influence on ER homeostasis implicates defects in NRF2-GSH or ER stress machineries as affecting alkylating therapy toxicity. Mol Cancer Ther; 15(12); 3000–14. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endoplasmic reticulum stress and the inflammatory basis of metabolic disease
Hotamisligil, G. S. (2010) · Cell · doi:10.1016/j.cell.2010.02.034 · Cited by 2,802
Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060
Shen, D.-W., Pouliot, L. M., Hall, M. D., & Gottesman, M. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005637 · Cited by 955 · cited 1×
“In addition, our cell models and CDDP studies (as in (39, 40)) have not observed a clear contribution of MRP1 (and MDR1) to cell survival in the context of alkylating drugs.”
High Levels of Nrf2 Determine Chemoresistance in Type II Endometrial Cancer
Jiang, T., Chen, N., Zhao, F., Wang, X.-J., Kong, B., Zheng, W., & Zhang, D. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0713 · Cited by 286 · cited 1×
“CDDP and paclitaxel toxicities were enhanced by NRF2 siRNA in SPEC-2 (highNRF2) but not Ishikawa (lowNRF2) endometrial cancer cells (63).”
Background
Research works printed but not linked: 59
- Hernandez-Aya, 2013, Adjuvant systemic therapies in breast cancer, Surg Clin North Am, 93, 473, 10.1016/j.suc.2012.12.002 · DOI
- Jones, 1993, Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer, Breast Cancer Res Treat, 26, 7, 10.1007/BF00668355 · doi:10.1007/bf00668355
- Omuro, 2013, Glioblastoma and other malignant gliomas: A clinical review, JAMA, 310, 1842, 10.1001/jama.2013.280319 · DOI · Paper page
- Friedman, 2000, Temozolomide and treatment of malignant glioma, Clin Cancer Res, 6, 2585
- Chan, 2013, Chemotherapy advances in small-cell lung cancer, J Thorac Dis, 5, S565
- Lin, 2012, Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy, Free Radic Biol Med, 52, 377, 10.1016/j.freeradbiomed.2011.10.487 · DOI · Paper page
- Drablos, 2004, Alkylation damage in DNA and RNA–repair mechanisms and medical significance, DNA Repair (Amst), 3, 1389, 10.1016/j.dnarep.2004.05.004 · DOI · Paper page
- Malet-Martino, 1999, The analysis of cyclophosphamide and its metabolites, Curr Pharm Des, 5, 561, 10.2174/1381612805666230110214643 · doi:10.2174/1381612805666230110214643
- Altieri, 2008, DNA damage and repair: From molecular mechanisms to health implications, Antioxid Redox Signal, 10, 891, 10.1089/ars.2007.1830 · DOI · Paper page
- Workman, 2006, A systems approach to mapping DNA damage response pathways, Science, 312, 1054, 10.1126/science.1122088 · DOI · Paper page
- Jaramillo, 2013, The emerging role of the Nrf2-Keap1 signaling pathway in cancer, Genes Dev, 27, 2179, 10.1101/gad.225680.113 · DOI · Paper page
- Li, 2012, Mechanism of chemical activation of Nrf2, PLoS One, 7, e35122, 10.1371/journal.pone.0035122 · DOI · Paper page
- Moore, 1991, Clinical pharmacokinetics of cyclophosphamide, Clin Pharmacokinet, 20, 194, 10.2165/00003088-199120030-00002 · doi:10.2165/00003088-199120030-00002
- Lin, 2009, Divergent effects of PERK and IRE1 signaling on cell viability, PLoS One, 4, e4170, 10.1371/journal.pone.0004170 · DOI · Paper page
- Novoa, 2001, Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha, J Cell Biol, 153, 1011, 10.1083/jcb.153.5.1011 · DOI · Paper page
- Lin, 2007, IRE1 signaling affects cell fate during the unfolded protein response, Science, 318, 944, 10.1126/science.1146361 · DOI · Paper page
- Ma, 2003, Delineation of a negative feedback regulatory loop that controls protein translation during endoplasmic reticulum stress, J Biol Chem, 278, 34864, 10.1074/jbc.M301107200 · DOI · Paper page
- Birk, 2013, Endoplasmic reticulum: Reduced and oxidized glutathione revisited, J Cell Sci, 126, 1604
- Raturi, 2007, Characterization of redox state and reductase activity of protein disulfide isomerase under different redox environments using a sensitive fluorescent assay, Free Radic Biol Med, 43, 62, 10.1016/j.freeradbiomed.2007.03.025 · DOI
- Chakravarthi, 2006, The role of glutathione in disulphide bond formation and endoplasmic-reticulum-generated oxidative stress, EMBO Rep, 7, 271, 10.1038/sj.embor.7400645 · DOI · Paper page
- Zanotto-Filho, 2016, Combined gene expression and RNAi screening to identify alkylation damage survival pathways from fly to human, PLoS One, 11, e0153970, 10.1371/journal.pone.0153970 · DOI
- Nikolova, 2010, Homologous recombination protects mammalian cells from replication-associated DNA double-strand breaks arising in response to methyl methanesulfonate, DNA Repair (Amst), 9, 1050, 10.1016/j.dnarep.2010.07.005 · DOI
- Zanotto-Filho, 2010, The pharmacological NFkappaB inhibitors BAY117082 and MG132 induce cell arrest and apoptosis in leukemia cells through ROS-mitochondria pathway activation, Cancer Lett, 288, 192, 10.1016/j.canlet.2009.06.038 · DOI
- Cox, 2007, High throughput method for assessment of cellular reduced glutathione in mammalian cells, J Environ Prot Sci, 1, 23
- Kim, 1995, Dibromobimane as a fluorescent crosslinking reagent, Anal Biochem, 225, 174, 10.1006/abio.1995.1131 · DOI
- Furukawa, 2005, BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase, Mol Cell Biol, 25, 162, 10.1128/MCB.25.1.162-171.2005 · DOI · Paper page
- Aguirre-Gamboa, 2013, SurvExpress: An online biomarker validation tool and database for cancer gene expression data using survival analysis, PLoS One, 8, e74250, 10.1371/journal.pone.0074250 · DOI · Paper page
- Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci Signal, 6, pl1, 10.1126/scisignal.2004088 · DOI · Paper page
- Cerami, 2012, The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data, Cancer Discov, 2, 401, 10.1158/2159-8290.CD-12-0095 · DOI · Paper page
- Komiya, 1998, Role of glutathione in cisplatin resistance in osteosarcoma cell lines, J Orthop Res, 16, 15, 10.1002/jor.1100160104 · DOI
- Koharyova, 2015, Thioredoxin system - a novel therapeutic target, Gen Physiol Biophys, 34, 221, 10.4149/gpb_2015006 · DOI
- Cullinan, 2003, Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival, Mol Cell Biol, 23, 7198, 10.1128/MCB.23.20.7198-7209.2003 · DOI · Paper page
- Li, 2008, The unfolded protein response regulator GRP78/BiP is required for endoplasmic reticulum integrity and stress-induced autophagy in mammalian cells, Cell Death Differ, 15, 1460, 10.1038/cdd.2008.81 · DOI · Paper page
- Ohta, 2008, Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth, Cancer Res, 68, 1303, 10.1158/0008-5472.CAN-07-5003 · DOI · Paper page
- Canning, 2015, Structural basis of Keap1 interactions with Nrf2, Free Radic Biol Med, 88, 101, 10.1016/j.freeradbiomed.2015.05.034 · DOI · Paper page
- Abazeed, 2013, Integrative radiogenomic profiling of squamous cell lung cancer, Cancer Res, 73, 6289, 10.1158/0008-5472.CAN-13-1616 · DOI · Paper page
- Sharp, 1998, Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines, Br J Cancer, 78, 175, 10.1038/bjc.1998.461 · DOI
- Wen, 2014, Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice, Am J Pathol, 184, 1299, 10.1016/j.ajpath.2014.01.025 · DOI
- Syu, 2016, Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia, Oncotarget, 7, 14659, 10.18632/oncotarget.7406 · DOI · Paper page
- Tsai-Turton, 2007, Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion, Toxicol Sci, 98, 216, 10.1093/toxsci/kfm087 · DOI · Paper page
- Gurgen, 2013, Chemoprotective effect of ascorbic acid, alpha-tocopherol, and selenium on cyclophosphamide-induced toxicity in the rat ovarium, Nutrition, 29, 777, 10.1016/j.nut.2012.11.004 · doi:10.1016/j.nut.2012.11.004
- Cuce, 2015, Chemoprotective effect of vitamin E in cyclophosphamide-induced hepatotoxicity in rats, Chem Biol Interact, 232, 7, 10.1016/j.cbi.2015.02.016 · doi:10.1016/j.cbi.2015.02.016
- Gross, 2004, Structure of Ero1p, source of disulfide bonds for oxidative protein folding in the cell, Cell, 117, 601, 10.1016/S0092-8674(04)00418-0 · DOI · Paper page
- Zhang, 2005, Differential adduction of proteins vs. deoxynucleosides by methyl methanesulfonate and 1-methyl-1-nitrosourea in vitro, Rapid Commun Mass Spectrom, 19, 438, 10.1002/rcm.1806 · doi:10.1002/rcm.1806
- Paik, 1984, Alkylation of protein by methyl methanesulfonate and 1-methyl-1-nitrosourea in vitro, Cancer Lett, 23, 9, 10.1016/0304-3835(84)90056-9 · doi:10.1016/0304-3835(84)90056-9
- Trezl, 1987, Studies on in vitro S-methylation of naturally occurring thiol compounds with N-methyl-N-nitrosourea and methyl methanesulfonate, Environ Res, 43, 417, 10.1016/S0013-9351(87)80042-7 · doi:10.1016/s0013-9351(87)80042-7
- Karasawa, 2013, Identification of cisplatin-binding proteins using agarose conjugates of platinum compounds, PLoS One, 8, e66220, 10.1371/journal.pone.0066220 · DOI
- Shi, 2016, ER stress and autophagy are involved in the apoptosis induced by cisplatin in human lung cancer cells, Oncol Rep, 35, 2606, 10.3892/or.2016.4680 · DOI
- Xu, 2015, Tolerance to endoplasmic reticulum stress mediates cisplatin resistance in human ovarian cancer cells by maintaining endoplasmic reticulum and mitochondrial homeostasis, Oncol Rep, 34, 3051, 10.3892/or.2015.4283 · DOI
- Rabik, 2008, Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress, J Pharmacol Exp Ther, 327, 442, 10.1124/jpet.108.141291 · DOI
- Jiang, 2009, Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells, Carcinogenesis, 30, 197, 10.1093/carcin/bgn220 · DOI
- Li, 2014, Cisplatin-induced senescence in ovarian cancer cells is mediated by GRP78, Oncol Rep, 31, 2525, 10.3892/or.2014.3147 · DOI
- Rocha, 2014, Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo, Cell Death Dis, 5, e1505, 10.1038/cddis.2014.465 · DOI · Paper page
- Ma, 2015, p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ, Med Oncol, 32, 69, 10.1007/s12032-015-0517-y · DOI
- Zanotto-Filho, 2015, Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas, Cancer Lett, 358, 220, 10.1016/j.canlet.2014.12.044 · DOI · Paper page
- Wang, 2006, Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents, Cancer Res, 66, 10983, 10.1158/0008-5472.CAN-06-2298 · DOI · Paper page
- Shibata, 2008, Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer, Gastroenterology, 135, 1358, 10.1053/j.gastro.2008.06.082 · DOI · Paper page
- Homma, 2009, Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer, Clin Cancer Res, 15, 3423, 10.1158/1078-0432.CCR-08-2822 · DOI · Paper page
- Singh, 2008, RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy, Cancer Res, 68, 7975, 10.1158/0008-5472.CAN-08-1401 · DOI · Paper page
Cited by
Cysteine metabolic circuitries: druggable targets in cancer
Bonifácio, V. D. B., Pereira, S. A., Serpa, J., & Vicente, J. B. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01156-1 · Cited by 264
Jiwaji, Z., Tiwari, S. S., Avilés-Reyes, R. X., Hooley, M., Hampton, D., Torvell, M., Johnson, D. A., McQueen, J., Baxter, P., Sabari-Sankar, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27702-w · Cited by 223
The Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-Kinase
Sanghvi, V. R., Leibold, J., Mina, M., Mohan, P., Berishaj, M., Li, Z., Miele, M. M., Lailler, N., Zhao, C., de Stanchina, E., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.031 · Cited by 155
“GSH production protects against reactive oxygen species (ROS) produced during oncogene driven cell proliferation or upon exposure to radiation and alkylating agents (DeNicola et al., 2011; Harris et al., 2015; Zanotto-Filho et al., 2016; Zhou et al., 2013).”
BackgroundNRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy
Sanghvi, V. R., Mohan, P., Singh, K., Cao, L., Berishaj, M., Wolfe, A. L., Schatz, J. H., Lailler, N., de Stanchina, E., Viale, A., et al. (2021) · Cancers · doi:10.3390/cancers13040639 · Cited by 27
Yuan, Y., Wang, C., Zhuang, X., Lin, S., Luo, M., Deng, W., Zhou, J., Liu, L., Mao, L., Peng, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32976-9 · Cited by 16
Metadata
- Authors
- Zanotto-Filho, A., Masamsetti, V. P., Loranc, E., Tonapi, S. S., Gorthi, A., Bernard, X., Gonçalves, R. M., Moreira, J. C. F., Chen, Y., & Bishop, A. J. R.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2016-12-01
- Volume
- 15
- Issue
- 12
- Pages
- 3000-3014
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2519151861
- Cited by
- 68
- References
- 4
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- NIH (K22ES012264, 1R15ES019128, and 1R01CA152063, CA054174)
- DOD CDMRP (W81XWH-14-1-0026)
- MCTI National Tax Service (485758/13-0)
- NCI (5T32CA148724)
- CPRIT (RP101491)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alkylating Agent–Induced NRF2 Blocks Endoplasmic Reticulum Stress–Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis. https://app.cochat.ai/papers/10.1158/1535-7163.mct-16-0271
- The paper
- Zanotto-Filho, A., Masamsetti, V. P., Loranc, E., Tonapi, S. S., Gorthi, A., Bernard, X., Gonçalves, R. M., Moreira, J. C. F., Chen, Y., & Bishop, A. J. R. (2016). Alkylating Agent–Induced NRF2 Blocks Endoplasmic Reticulum Stress–Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-16-0271
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.